I. Benko et al., Comparison of the toxicity of fluconazole and other azole antifungal drugsto murine and human granulocyte-macrophage progenitor cells in vitro, J ANTIMICRO, 43(5), 1999, pp. 675-681
We studied the inhibitory effects on colony formation by granulocyte-macrop
hage colony forming units (cfu-gm) of eight azole antifungal agents in vitr
o. All agents, except fluconazole, inhibited colony formation dose-dependen
tly with 50% inhibitory concentrations (IC50) in the range of 0.78-49 mu mo
l/L in cultures of murine and human bone marrow. For human cells, the IC50
values were 0.553 mg/L for itraconazole, 1.24 mg/L for saperconazole, 2.58
mg/L for clotrimazole, 5.33 mg/L for miconatole, 6.17 mg/L for econazole, 6
.27 mg/L for ketocanazole and 8.38 mg/L for oxiconazole. The IC50 of itraco
nazole for human cfu-gm in vitro was similar to the plasma level of this dr
ug recommended far systemic antifungal therapy (>0.5 mg/L) thus indicating
the potential clinical relevance of our data. The IC50 of ketoconazole for
human cfu-gm in vitro may be exceeded by plasma levels produced in vivo by
high (greater than or equal to 400 mg) doses, whereas fluconazole failed to
reduce colony formation by 50% even at 100 mg/L, a concentration not reach
ed in vivo even after extremely high doses (2000 mg/day). To most of the dr
ugs studied, murine progenitor cells seemed to be less sensitive than the h
uman ones. There was, however, a close correlation between the murine and h
uman log IC50 values of the drugs (r(2) = 0.964, P < 0.001), suggesting tha
t cultures of murine bone marrow may be suitable to predict the in-vitro to
xicity of azole antifungals to human cfu-gm.